Communiqués ImmuCell Corporation

Actions

ICCC

US4525253062

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 12/06/2026			Varia. 5j.	Varia. 1 janv.
9,680 ^USD	-0,62 %		+0,73 %	+57,40 %

15/05	Transcript : ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026
14/05	ImmuCell Corporation publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

14/05	ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026	AQ
07/05	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026	AQ
22/04	ImmuCell : Corporate Presentation (Investor Relations April 2026 Final)	PU
13/04	ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors	AQ
08/04	ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results	AQ
18/03	ImmuCell : 03-18-26 – ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board	PU
18/03	ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board	AQ
04/03	ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025	AQ
18/02	ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025	AQ
08/01	ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025	AQ
07/01	ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus	AQ
24/12	ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®	AQ
13/11	ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025	AQ
06/11	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025	AQ
04/11	ImmuCell Announces Onboarding of New CEO and Related Management Changes	AQ
07/10/25	ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025	AQ
29/09/25	ImmuCell Announces Selection of its Next President and CEO	AQ
14/08/25	ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025	AQ
12/08/25	ImmuCell Announces Bank Debt Refinancing	AQ
07/08/25	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025	AQ
09/07/25	ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025	AQ
25/06/25	ImmuCell Embarks on CEO Succession Planning Process	AQ
05/06/25	ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders	AQ
14/05/25	ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025	AQ
12/05/25	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025	AQ